Imperial College London
Portrait Picture

ProfessorPaoloMuraro

Faculty of Medicine, Department of Brain Sciences

Professor of Neurology - Neuroimmunology and Immunotherapy
 
 
 
//

Contact

 

p.muraro Website

 
 
//

Assistant

 

Mrs Gearoidin Beazley +44 (0)20 7594 7047

 
//

Location

 

E415Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cohen:2019:10.1016/j.bbmt.2019.02.014,
author = {Cohen, JA and Baldassari, LE and Atkins, HL and Bowen, JD and Bredeson, C and Carpenter, PA and Corboy, JR and Freedman, MS and Griffith, LM and Lowsky, R and Majhail, NS and Muraro, PA and Nash, RA and Pasquini, MC and Sarantopoulos, S and Savani, BN and Storek, J and Sullivan, KM and Georges, GE},
doi = {10.1016/j.bbmt.2019.02.014},
journal = {Biology of Blood and Marrow Transplantation},
pages = {845--854},
title = {Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation},
url = {http://dx.doi.org/10.1016/j.bbmt.2019.02.014},
volume = {25},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, central nervous system demyelinating and degenerative disease. Approved disease modifying therapies may be incompletely effective in some patients with highly active relapsing disease and high risk of disability. Immunoablative or myeloablative therapy followed by autologous hematopoietic cell transplantation (AHCT) has been investigated in retrospective studies, clinical trials, and meta-analyses/systematic reviews as an approach to address this unmet clinical need. On behalf of the American Society for Blood and Bone Marrow Transplantation (ASBMT), a panel of experts in AHCT and MS convened to review available evidence and make recommendations on MS as an indication for AHCT. Review of recent literature identified eight retrospective studies, eight clinical trials, and three meta-analyses/systematic reviews. In aggregate, these studies indicate that AHCT is an efficacious and safe treatment for active relapsing forms of MS to prevent clinical relapses, MRI lesion activity, and disability worsening, and to reverse disability, without unexpected adverse events. Based on the available evidence, the ASBMT recommends that treatment-refractory relapsing MS with high risk of future disability be considered a "standard of care, clinical evidence available" indication for AHCT. Collaboration of neurologists with expertise in treating MS and transplant physicians with experience performing AHCT for autoimmune disease is crucial for appropriate patient selection and optimizing transplant procedures to improve patient outcomes. Transplant centers in the United States and Canada are strongly encouraged to report baseline and outcomes data on patients receiving AHCT for multiple sclerosis to the Center for International Blood and Marrow Transplant Research.
AU  - Cohen,JA
AU  - Baldassari,LE
AU  - Atkins,HL
AU  - Bowen,JD
AU  - Bredeson,C
AU  - Carpenter,PA
AU  - Corboy,JR
AU  - Freedman,MS
AU  - Griffith,LM
AU  - Lowsky,R
AU  - Majhail,NS
AU  - Muraro,PA
AU  - Nash,RA
AU  - Pasquini,MC
AU  - Sarantopoulos,S
AU  - Savani,BN
AU  - Storek,J
AU  - Sullivan,KM
AU  - Georges,GE
DO  - 10.1016/j.bbmt.2019.02.014
EP  - 854
PY  - 2019///
SN  - 1083-8791
SP  - 845
TI  - Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation
T2  - Biology of Blood and Marrow Transplantation
UR  - http://dx.doi.org/10.1016/j.bbmt.2019.02.014
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30794930
UR  - https://www.bbmt.org/article/S1083-8791(19)30139-9/fulltext
UR  - http://hdl.handle.net/10044/1/67612
VL  - 25
ER  -
Download